Recently,Hisicore innovative drugsHSK21542sliceⅠThe phase I clinical trial completed the enrollment and medication administration for the first participant. This timeⅠThe phase I clinical trial is forEvaluationHSK21542Safety, tolerance, and pharmacokinetics of the tablet in healthy subjects, absolute bioavailabilityand the impact of food on pharmacokinetics。

Innovative drugsHSK21542sliceIt is Haisco.Independently developed peripheralkappaA selective agonist of the opioid receptor with high selectivity and affinityGProteins cooperate in regulating potassium and calcium ion flows, by blocking itching signal transmission and suppressing the excitability of the dorsal root ganglia and peripheral sensory nerves, reducing the release of inflammatory factors and neurotransmitters, thereby inhibiting itching.The drug has received a clinical trial notice and is officially underway.ⅠThe phase I clinical trial has completed the first dose administration recently, and the project is progressing smoothly.

This development of oral formulations will expand the scope of applicable patients, improve patient adherence to treatment, enhance the convenience of administration, meet more clinical medication needs, and provide more treatment options for patients.